SlideShare a Scribd company logo
Biopharma PEG https://www.biochempeg.com
Claudin6 (CLDN6): A Emerging Target For Solid
Tumor
In June 2023, BioNTech announced the first human trial data of BNT211 at the American
Society of Clinical Oncology (ASCO). TORL BioTherapeutics also disclosed the first
clinical data of its CLDN6 ADC drug TORL-1-23. These early clinical results provide
strong support for Claudin-6 (CLDN6) as a potential target in solid tumors, especially
ovarian cancers and testicular cancers. CLDN6, as a member of the Claudins family,
will be a emerging target for solid tumor therapy after Claudin 18.2 (ClDN18.2).
BNT211 is a combination therapy of CLDN6-targeting CAR-T and mRNA vaccine,
including autologous CAR-T targeting CLDN6 and CLDN6-encoded nanoparticle mRNA
vaccine CARVac. The mRNA vaccine enhances its efficacy by stimulating further
expansion of CAR-T cells in vivo by expressing CLDN6 on the surface of
antigen-presenting cells. Combined with the newly published study data, the researchers
said that CLDN6 CAR-T infusion alone or in combination with CARVac was safe and
showed efficacy in patients with CLDN6-positive cancers, and the results were superior to
data from other solid tumor CAR T trials.
1. Introduction to CLDN6
The Claudins (CLDNs) protein family was first cloned and named from chicken liver by
Furuse Mikio et al. in 1998, and is an important part of tight junctions (TJs). Tight junctions
are mainly composed of occludin, CLDNs, and tight junction adhesion molecules. At
present, 27 members of the Claudin family have been discovered, and with the deepening
of research, members of the Claudins family will continue to grow, 24 of which are
expressed in mammals. A large number of studies have confirmed that the Claudins
family is an essential skeleton protein of TJs, mainly expressed in a tissue-specific
manner in endothelial cells or epithelial cells.
According to the level of sequence homology of different claudins, these members can be
divided into two types, namely classic claudins and non-classical
Biopharma PEG https://www.biochempeg.com
claudins. CLDN6 belongs to the classical claudins and is homologous to CLDN1, CLDN2,
CLDN3, CLDN4, CLDN5, CLDN7, CLDN8, CLDN9, CLDN10, CLDN14, CLDN15,
CLDN17 and CLDN19. 2001, Turksen K. Identification of CLDN6 from differential display
analysis of differentiated embryoid bodies (EBs). However, Turksen K. was not the first to
isolate CLDN6. CLDN6 cDNA was first isolated from an ectoderm-specific library by
Harrison S.M.'s team in 1995.
Claudins members are widely distributed in different tissues and organs, and their
expression has diversified characteristics. In recent years, a large number of research
data have revealed that abnormal expression of Claudins is associated with a variety of
tumors, and more potential targets of the Claudins family have emerged for clinical
diagnosis and treatment of tumors (Figure 1). It plays a role not only in cancer, but also in
other diseases.
For example, aberrant expression of CLDN1 can lead to sclerosing cholangitis and
ichthyosis. Increased CLDN3 is associated with decreased alveolar barrier function. In the
field of cancer immunotherapy, CLDN18.2, an isomer of Claudins family member CLDN18,
has become a hot target for competition by pharmaceutical companies. Now, CLDN6 is a
potential target of the Claudins family, and the development of tumor-targeted drugs is
also in full swing.
Biopharma PEG https://www.biochempeg.com
Figure 1 Clinical applications of claudin-targeting agents in the diagnosis, prognosis and treatment of
cancer.
(Source: References [1])
2. Structure And Function of CLDN6
As one of the 27 members of the CLDN family, CLDN6 is an important molecule that
makes up the tight junction between cells. The CLDN6 gene, located on chromosome
16p13.3, is composed of 220 amino acids with a molecular weight of 23kDa and contains
three exons. Claudins members have similar structures. As shown in Figure 2, CLDN6
has four transmembrane domains, a short cytoplasmic N-terminal, a C-terminal
cytoplasmic domain, two extracellular domains (a larger ECL1 and a smaller ECL2), and a
short intracellular ring, consistent with other CLDNNS. CLDN6 has a C-terminal PDZ
Biopharma PEG https://www.biochempeg.com
binding site, which enables CLDN6 to interact with some proteins in the cell, and plays an
important role in cell junctions and epithelial tissue permeability.
The PDZ binding domain of ECL1 and cytoplasmic C-terminal is a typical domain of CLDN.
ECL1 crosses between cells to form ion-selective pores. The position and charge of
amino acids in the ECL1 region of different claudins are very different, and the difference
of C-terminal sequence is another difference point that distinguishes the members of
claudin. The PDZ binding sequence at the C-terminal and some potential phosphorylation
sites enable claudin to directly act on its specific structural domain with ZO-1, ZO-2, ZO-3,
MUPP1, etc. which contain PDZ structure in the cytoplasm, and ZO-1 and ZO-2 can
directly connect with actin filament. Thus TJ protein can form a stable system with the
intracellular skeleton structure.
Figure 2. Structure diagram of CLDN6
(Source: References [2])
As a member of the claudin protein family, CLDN6 also has the functions of tight junction
permeability regulation and barrier formation. Regarding the permeability regulation
function, CLDN6 is critical for the regulation of chloride ion permeability in neonatal renal
proximal tubules and the regulation of ion transport in the lymphatic sac epithelium of the
inner ear. On the barrier side, CLDN6 is important for maintaining the lung epithelial
barrier. In addition, CLDN6 is mainly involved in the formation of the epidermal
Biopharma PEG https://www.biochempeg.com
permeability barrier (EPB) during preterm birth. Unlike other claudin members, CLDN6 is
the only CLDN with potential specificity because it activates cell adhesion signals and
regulates the activity of nuclear receptors. CLDN6 is regulated by stimulation and
transcription factors, DNA methylation, phosphorylation, and palmitoylation.
3. Research Projects of CLDN6
CLDN6 studies emerging immunotherapies for the treatment of cancer,
including monoclonal antibodies, bispecific antibodies (BsAbs), antibody drug conjugates
(ADCs) and CAR-T-cells therapy. CLDN6 is applied in monoclonal antibodies for testicular
germ cell tumor, BsAbs for ovarian carcinoma, ADCs for hepatocellular carcinoma, and
CAR-T-cells therapy for ovarian carcinoma. At present, there are a total of 7 clinical
projects, including 1 monoclonal antibodies project, 2 bispecific antibodies projects, 2
ADC drug projects, and 2 CAR-T therapy projects.
Figure 3. Clinical application of CLDN6 immunotherapy
(Source: References [2])
Biopharma PEG https://www.biochempeg.com
3.1 BNT211 & BNT142
BioNTech announced several updates to its CLDN portfolio at the 2023 ASCO Annual
Meeting, including BNT211 and BNT142. Among them, the most striking is the latest
research results of BNT211 for the treatment of solid tumors.
BNT211 is a CLDN6-targeted CAR T cell therapy developed by BioNetech. The therapy is
designed to induce robust immune responses against various CLDN6-positive solid
tumors, such as ovarian, sarcoma, testicular, endometrial and gastric cancers. BNT211 is
currently in a phase 1/2 trial with or without CARVac in patients with CLDN6-positive
relapsed/refractory advanced solid tumors. The latest results show that in patients with
CLDN6-positive relapsed/refractory advanced solid tumors, CARVac, with or without
CLDN6-encoding mRNA vaccine, exhibited positive activity and manageable safety data.
As of March 2023, among the 17 evaluable patients who received BNT211 with or without
CARVac, the overall objective response rate (ORR) was 41%, and the disease control
rate (DCR) reached 65%. One of the patients with testicular cancer who received
automated BNT211 treatment achieved surgical complete response (sCR). Five additional
patients achieved a partial response (PR) and three patients achieved stable disease
(SD). During the automated manufacturing process, BNT211 maintained its efficacy,
which supports the scale-up of the production process.
BNT142 is an mRNA vaccine encoding a CD3xCLDN6 bispecific. After intravenous
injection, BNT142 is directed to the liver, where the two RNAs are translated, assembled
and secreted into the circulation as antibodies. Since mRNA vaccine toxicity tends to
accumulate in the liver, the report of hepatotoxicity is of great significance. BNT142 is
currently undergoing a Phase I dose escalation clinical trial.
3.2 TORL-1-23
TORL-1-23 is an ADC drug developed by TORL BioTherapeutics by conjugating
anti-CLDN6 monoclonal antibody and tubulin inhibitor MMAE via a cleavable linker. TORL
BioTherapeutics presented the first clinical data of its Claudin6 ADC drug TORL-1-23 at
ASCO 2023. Phase I clinical trials have shown positive efficacy, among 25 refractory
cancer patients who received an average of 5 previous treatments, 28% of patients
Biopharma PEG https://www.biochempeg.com
achieved confirmed remission. After establishing the recommended phase II dose (RP2D),
TORL plans to conduct an expansion cohort study in CLDN6-positive ovarian cancer and
non-small cell lung cancer (NSCLC), as well as other CLDN6-positive cancers.
3.3 DS-9606
DS-9606 is an ADC drug targeting CLDN6 developed by DaiichiSankyo. The results of
preclinical research data show that the targeted Claudin6 ADC constructed on this
technology platform exhibits significant anti-tumor activity. DS-9606 is currently
undergoing a Phase 1 clinical study, which aims to evaluate the safety and tolerability of
DS9606a in patients with advanced solid tumors. Secondary objectives of the study will
evaluate the pharmacokinetic properties of DS-9606a, investigate the duration of
response and progression-free survival of DS-9606a, and assess the immunogenicity of
DS-9606a.
3.4 AMG 794
AMG794 is a bispecific antibody with extended half-life developed based on the bispecific
T cellengager (BITE) technology platform, which can bind to human and cynomolgus
monkey CLDN6 and CD3. AMG794 can reprogram T cells to kill CLDN6-expressing tumor
cells and is currently enrolling patients in a Phase I clinical trial.
3.5 TJ-C64B
TJ-C64B is a bispecific antibody that simultaneously targets the tumor antigen claudin6
and the T cell costimulatory molecule 4-1BB for the treatment of Claudin6-positive tumors.
TJ-C64B can conditionally activate T cells by binding to CLDN6, thereby providing more
precise and efficient activation of the immune system while reducing the risk of systemic
toxicity. Currently, TJ-C64B is in the preclinical research stage.
4. CLDN6 In tumors And Other Diseases
CLDN6 and other family proteins play an important role in the formation of tight junctions
between epithelial cells and endothelial cells. The CLDN family maintains the balance of
the intracellular environment through cell barriers, paracellular transport and signal
transduction. Abnormal expression of family proteins such as CLDN6 can impair the
Biopharma PEG https://www.biochempeg.com
function of TJs and reduce the barrier function, leading to increased tissue permeability,
and ultimately leading to the occurrence of various diseases including genetics, allergic
diseases, infectious diseases of various systems, and even tumors . At present, the
research on CLDN6 mainly focuses on tumors, especially ovarian cancer, testicular
cancer, breast cancer, cervical cancer and endometrial cancer.
4.1 CLDN6 and tumors
Tumor cells often exhibit loss of intercellular tight junctions, which may also be an
important step in the development of tumor metastasis. Altered tight junction protein
permeability will result in more nutrients and other factors infiltrated for tumor growth. As
the main structure of tight junctions, abnormal expression of Claudins can lead to
structural damage and functional impairment of epithelial cells and endothelial cells, and it
is abnormally expressed in tumors of various epithelial origins. For example, the
expression of Cliaudin2 in prostate cancer and breast cancer, Claudin3 in kidney cancer
and bladder cancer, and Claudin4 in kidney cancer and liver cancer are down-regulated.
Unlike other CLDNNS, CLDN6 is a tumor-specific protein that is present in a variety of
solid tumors, including the ovaries, endometrium, lungs, stomach, and testes, but not in
healthy adult tissue. Based on this, more and more studies on the role of CLDN6 in cancer
have been conducted in recent years. With the continuous disclosure of research results,
CLDN6 has gradually become an ideal target for tumor therapy.
4.2 CLDN6 and other diseases such as polycystic ovary syndrome
Studies have confirmed that CLDN6 is highly expressed in polycystic ovary syndrome
(PCOS) and Granular Cells (GC), weakening the expression of CLDN6 can inhibit the
proliferation of ovarian GC in PCOS rats and induce GC apoptosis. PCOS is
characterized by oligomenorrhea, hyperandrogenism, and polycystic ovarian changes,
affecting 5% to 20% of women of reproductive age worldwide. In women with PCOS, GCs
proliferate abnormally and are associated with overproduction of androgens in the ovaries.
Another study reported that inhibiting the expression of CLDN6 can inhibit the proliferation,
migration and invasion of endometriosis cells. Endometriosis is a common clinical
gynecological disease, and the incidence rate is relatively high in women of childbearing
age. Patients often have symptoms such as excessive menstrual flow and dysmenorrhea.
Biopharma PEG https://www.biochempeg.com
The above studies imply that CLDN6 may serve as a potential target for the treatment of
PCOS or endometriosis.
5. Conclusion
There are a variety of drug therapies targeting Claudin6, including monoclonal
antibodies, ADCs, bispecific antibodies, and CAR-T cells. With more and more
studies on the tight junction protein family, the molecular mechanism and drug research
related to tumors of the CLDNs family is becoming a hot focus. Following CLDN18.2,
CLDN6 is also a key member of tight junction proteins. Abnormal expression of CLDN6
plays an important role in ovarian cancer and other malignant tumors, especially
gynecological tumors. At present, some positive early clinical results have been
announced by ASCO in 2023, which is expected to set off a new upsurge in solid tumor
research and development in the future, which deserves continuous attention.
As a professional PEG supplier, Biopharma PEG supplies a variety of PEG linkers with
various reactive groups in GMP or non-GMP grades to continuously assist your ADC &
PROTAC research and development.
References:
[1] Li, Jian. "Targeting claudins in cancer: diagnosis, prognosis and therapy." American
journal of cancer research 11.7 (2021): 3406.
[2] Huinan Qu, Qiu Jin and Chengshi Quan“CLDN6: From Traditional Barrier Function to
Emerging Roles in Cancers”Int. J. Mol. Sci. 2021, 22(24)
[3] Turksen K., Troy T.C. Claudin-6: A novel tight junction molecule is developmentally
regulated in mouse embryonic epithelium. Dev. Dyn. Off. Publ. Am. Assoc. Anat.
2001;222:292–300.
[4]. Timothy A. Yap, et al. A phase I/II dose escalation trial with expansion cohorts to
evaluate safety and preliminary efficacy of BNT142 in patients with prospectively
confirmed claudin 6-positive solid tumors. 2023 ASCO, Abs TPS2669.
[5]. Gottfried E. Konecny, et al. Initial results of dose finding in a first-in-human phase 1
study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Biopharma PEG https://www.biochempeg.com
in patients with advanced solid tumors. 2023 ASCO, Abs 3082.
[6] Du H, Yang X, Fan J, et al. Claudin 6: Therapeutic prospects for tumours, and
mechanisms of expression and regulation[J]. Molecular Medicine Reports, 2021, 24(3):
1-9.
[7] ASCO 2023 – Claudin 6 Makes A Splash In Ovarian Cancer,
https://www.benzinga.com/general/biotech/23/06/32780740/asco-2023-claudin-6-makes-
a-splash-in-ovarian-cancer
[8]. John B. A. G. Haanen,et al. CLDN6 CAR-T cell therapy of relapsed/refractory solid
tumors ±a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01
phase 1 trial using an automated product. 2023 ASCO, Abs 2518.
Related articles:
[1] ADC Drugs Targeting Claudin18.2
[2] Claudin18.2 Targeted Therapies In Cancer

More Related Content

Similar to Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf

Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfDoriaFang
 
Lnc rna pcat29 suppresses cell proliferation, invasion, and migration in rena...
Lnc rna pcat29 suppresses cell proliferation, invasion, and migration in rena...Lnc rna pcat29 suppresses cell proliferation, invasion, and migration in rena...
Lnc rna pcat29 suppresses cell proliferation, invasion, and migration in rena...Clinical Surgery Research Communications
 
Summary of ADCs in Clinical Phase 3.pdf
Summary of ADCs in Clinical Phase 3.pdfSummary of ADCs in Clinical Phase 3.pdf
Summary of ADCs in Clinical Phase 3.pdfHuateng Pharma
 
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...Mark Lipstein
 
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...EduConnections
 
Metastasis- Cancer cell migration
Metastasis- Cancer cell migrationMetastasis- Cancer cell migration
Metastasis- Cancer cell migrationQussai Abbas
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...JohnJulie1
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...AnonIshanvi
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...daranisaha
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...EditorSara
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...NainaAnon
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...semualkaira
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...semualkaira
 
Summary of PROTAC And Other Targeted Protein Degradation Technologies.pdf
Summary of PROTAC And Other Targeted Protein Degradation Technologies.pdfSummary of PROTAC And Other Targeted Protein Degradation Technologies.pdf
Summary of PROTAC And Other Targeted Protein Degradation Technologies.pdfDoriaFang
 
Global antibody-drug-conjugate-adc-clinical-trial-review
Global antibody-drug-conjugate-adc-clinical-trial-reviewGlobal antibody-drug-conjugate-adc-clinical-trial-review
Global antibody-drug-conjugate-adc-clinical-trial-reviewEchoHan4
 
Global ADC Clinical Trial Review
Global ADC Clinical Trial ReviewGlobal ADC Clinical Trial Review
Global ADC Clinical Trial ReviewCreative Biolabs
 
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...DoriaFang
 

Similar to Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf (20)

Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
 
Lnc rna pcat29 suppresses cell proliferation, invasion, and migration in rena...
Lnc rna pcat29 suppresses cell proliferation, invasion, and migration in rena...Lnc rna pcat29 suppresses cell proliferation, invasion, and migration in rena...
Lnc rna pcat29 suppresses cell proliferation, invasion, and migration in rena...
 
GSK Oncology 2017
GSK Oncology 2017GSK Oncology 2017
GSK Oncology 2017
 
Summary of ADCs in Clinical Phase 3.pdf
Summary of ADCs in Clinical Phase 3.pdfSummary of ADCs in Clinical Phase 3.pdf
Summary of ADCs in Clinical Phase 3.pdf
 
2012-Feyen-EDIM-FutureOncology.pdf
2012-Feyen-EDIM-FutureOncology.pdf2012-Feyen-EDIM-FutureOncology.pdf
2012-Feyen-EDIM-FutureOncology.pdf
 
SRC TMCOS 2015 2
SRC TMCOS 2015 2SRC TMCOS 2015 2
SRC TMCOS 2015 2
 
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
 
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...
 
Metastasis- Cancer cell migration
Metastasis- Cancer cell migrationMetastasis- Cancer cell migration
Metastasis- Cancer cell migration
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
 
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...
 
Summary of PROTAC And Other Targeted Protein Degradation Technologies.pdf
Summary of PROTAC And Other Targeted Protein Degradation Technologies.pdfSummary of PROTAC And Other Targeted Protein Degradation Technologies.pdf
Summary of PROTAC And Other Targeted Protein Degradation Technologies.pdf
 
Global antibody-drug-conjugate-adc-clinical-trial-review
Global antibody-drug-conjugate-adc-clinical-trial-reviewGlobal antibody-drug-conjugate-adc-clinical-trial-review
Global antibody-drug-conjugate-adc-clinical-trial-review
 
Global ADC Clinical Trial Review
Global ADC Clinical Trial ReviewGlobal ADC Clinical Trial Review
Global ADC Clinical Trial Review
 
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
 

More from DoriaFang

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfDoriaFang
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfDoriaFang
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfDoriaFang
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfDoriaFang
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfDoriaFang
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfDoriaFang
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfDoriaFang
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDoriaFang
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfDoriaFang
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfDoriaFang
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfDoriaFang
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfDoriaFang
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfDoriaFang
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfDoriaFang
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfDoriaFang
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfDoriaFang
 
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfNectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfDoriaFang
 
PROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfPROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfDoriaFang
 
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdfAptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdfDoriaFang
 
Summary of Molecular Glues Approved or in Clinical Trial.pdf
Summary of Molecular Glues Approved or in Clinical Trial.pdfSummary of Molecular Glues Approved or in Clinical Trial.pdf
Summary of Molecular Glues Approved or in Clinical Trial.pdfDoriaFang
 

More from DoriaFang (20)

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
 
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfNectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
 
PROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfPROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdf
 
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdfAptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
 
Summary of Molecular Glues Approved or in Clinical Trial.pdf
Summary of Molecular Glues Approved or in Clinical Trial.pdfSummary of Molecular Glues Approved or in Clinical Trial.pdf
Summary of Molecular Glues Approved or in Clinical Trial.pdf
 

Recently uploaded

Vendors of country report usefull datass
Vendors of country report usefull datassVendors of country report usefull datass
Vendors of country report usefull datassDilipParmar63
 
Constitution of Company Article of Association
Constitution of Company Article of AssociationConstitution of Company Article of Association
Constitution of Company Article of Associationseri bangash
 
Potato Flakes Manufacturing Plant Project Report.pdf
Potato Flakes Manufacturing Plant Project Report.pdfPotato Flakes Manufacturing Plant Project Report.pdf
Potato Flakes Manufacturing Plant Project Report.pdfhostl9518
 
Falcon Invoice Discounting Setup for Small Businesses
Falcon Invoice Discounting Setup for Small BusinessesFalcon Invoice Discounting Setup for Small Businesses
Falcon Invoice Discounting Setup for Small BusinessesFalcon investment
 
Engagement Rings vs Promise Rings | Detailed Guide
Engagement Rings vs Promise Rings | Detailed GuideEngagement Rings vs Promise Rings | Detailed Guide
Engagement Rings vs Promise Rings | Detailed GuideCharleston Alexander
 
Salesforce in Life Sciences - Best Ways to Leverage The CRM for Clinical Trials
Salesforce in Life Sciences - Best Ways to Leverage The CRM for Clinical TrialsSalesforce in Life Sciences - Best Ways to Leverage The CRM for Clinical Trials
Salesforce in Life Sciences - Best Ways to Leverage The CRM for Clinical TrialsFEXLE
 
8 Questions B2B Commercial Teams Can Ask To Help Product Discovery
8 Questions B2B Commercial Teams Can Ask To Help Product Discovery8 Questions B2B Commercial Teams Can Ask To Help Product Discovery
8 Questions B2B Commercial Teams Can Ask To Help Product DiscoveryDesmond Leo
 
Global Interconnection Group Joint Venture[960] (1).pdf
Global Interconnection Group Joint Venture[960] (1).pdfGlobal Interconnection Group Joint Venture[960] (1).pdf
Global Interconnection Group Joint Venture[960] (1).pdfHenry Tapper
 
IPTV Subscription UK: Your Guide to Choosing the Best Service
IPTV Subscription UK: Your Guide to Choosing the Best ServiceIPTV Subscription UK: Your Guide to Choosing the Best Service
IPTV Subscription UK: Your Guide to Choosing the Best ServiceDragon Dream Bar
 
Future of Trade 2024 - Decoupled and Reconfigured - Snapshot Report
Future of Trade 2024 - Decoupled and Reconfigured - Snapshot ReportFuture of Trade 2024 - Decoupled and Reconfigured - Snapshot Report
Future of Trade 2024 - Decoupled and Reconfigured - Snapshot ReportDubai Multi Commodity Centre
 
USA classified ads posting – best classified sites in usa.pdf
USA classified ads posting – best classified sites in usa.pdfUSA classified ads posting – best classified sites in usa.pdf
USA classified ads posting – best classified sites in usa.pdfsuperbizness1227
 
The Inspiring Personality To Watch In 2024.pdf
The Inspiring Personality To Watch In 2024.pdfThe Inspiring Personality To Watch In 2024.pdf
The Inspiring Personality To Watch In 2024.pdfinsightssuccess2
 
Creative Ideas for Interactive Team Presentations
Creative Ideas for Interactive Team PresentationsCreative Ideas for Interactive Team Presentations
Creative Ideas for Interactive Team PresentationsSlidesAI
 
zidauu _business communication.pptx /pdf
zidauu _business  communication.pptx /pdfzidauu _business  communication.pptx /pdf
zidauu _business communication.pptx /pdfzukhrafshabbir
 
FEXLE- Salesforce Field Service Lightning
FEXLE- Salesforce Field Service LightningFEXLE- Salesforce Field Service Lightning
FEXLE- Salesforce Field Service LightningFEXLE
 
The Truth About Dinesh Bafna's Situation.pdf
The Truth About Dinesh Bafna's Situation.pdfThe Truth About Dinesh Bafna's Situation.pdf
The Truth About Dinesh Bafna's Situation.pdfMont Surfaces
 
Copyright: What Creators and Users of Art Need to Know
Copyright: What Creators and Users of Art Need to KnowCopyright: What Creators and Users of Art Need to Know
Copyright: What Creators and Users of Art Need to KnowMiriam Robeson
 
What is social media.pdf Social media refers to digital platforms and applica...
What is social media.pdf Social media refers to digital platforms and applica...What is social media.pdf Social media refers to digital platforms and applica...
What is social media.pdf Social media refers to digital platforms and applica...AnaBeatriz125525
 
A Brief Introduction About Jacob Badgett
A Brief Introduction About Jacob BadgettA Brief Introduction About Jacob Badgett
A Brief Introduction About Jacob BadgettJacobBadgett
 
Event Report - IBM Think 2024 - It is all about AI and hybrid
Event Report - IBM Think 2024 - It is all about AI and hybridEvent Report - IBM Think 2024 - It is all about AI and hybrid
Event Report - IBM Think 2024 - It is all about AI and hybridHolger Mueller
 

Recently uploaded (20)

Vendors of country report usefull datass
Vendors of country report usefull datassVendors of country report usefull datass
Vendors of country report usefull datass
 
Constitution of Company Article of Association
Constitution of Company Article of AssociationConstitution of Company Article of Association
Constitution of Company Article of Association
 
Potato Flakes Manufacturing Plant Project Report.pdf
Potato Flakes Manufacturing Plant Project Report.pdfPotato Flakes Manufacturing Plant Project Report.pdf
Potato Flakes Manufacturing Plant Project Report.pdf
 
Falcon Invoice Discounting Setup for Small Businesses
Falcon Invoice Discounting Setup for Small BusinessesFalcon Invoice Discounting Setup for Small Businesses
Falcon Invoice Discounting Setup for Small Businesses
 
Engagement Rings vs Promise Rings | Detailed Guide
Engagement Rings vs Promise Rings | Detailed GuideEngagement Rings vs Promise Rings | Detailed Guide
Engagement Rings vs Promise Rings | Detailed Guide
 
Salesforce in Life Sciences - Best Ways to Leverage The CRM for Clinical Trials
Salesforce in Life Sciences - Best Ways to Leverage The CRM for Clinical TrialsSalesforce in Life Sciences - Best Ways to Leverage The CRM for Clinical Trials
Salesforce in Life Sciences - Best Ways to Leverage The CRM for Clinical Trials
 
8 Questions B2B Commercial Teams Can Ask To Help Product Discovery
8 Questions B2B Commercial Teams Can Ask To Help Product Discovery8 Questions B2B Commercial Teams Can Ask To Help Product Discovery
8 Questions B2B Commercial Teams Can Ask To Help Product Discovery
 
Global Interconnection Group Joint Venture[960] (1).pdf
Global Interconnection Group Joint Venture[960] (1).pdfGlobal Interconnection Group Joint Venture[960] (1).pdf
Global Interconnection Group Joint Venture[960] (1).pdf
 
IPTV Subscription UK: Your Guide to Choosing the Best Service
IPTV Subscription UK: Your Guide to Choosing the Best ServiceIPTV Subscription UK: Your Guide to Choosing the Best Service
IPTV Subscription UK: Your Guide to Choosing the Best Service
 
Future of Trade 2024 - Decoupled and Reconfigured - Snapshot Report
Future of Trade 2024 - Decoupled and Reconfigured - Snapshot ReportFuture of Trade 2024 - Decoupled and Reconfigured - Snapshot Report
Future of Trade 2024 - Decoupled and Reconfigured - Snapshot Report
 
USA classified ads posting – best classified sites in usa.pdf
USA classified ads posting – best classified sites in usa.pdfUSA classified ads posting – best classified sites in usa.pdf
USA classified ads posting – best classified sites in usa.pdf
 
The Inspiring Personality To Watch In 2024.pdf
The Inspiring Personality To Watch In 2024.pdfThe Inspiring Personality To Watch In 2024.pdf
The Inspiring Personality To Watch In 2024.pdf
 
Creative Ideas for Interactive Team Presentations
Creative Ideas for Interactive Team PresentationsCreative Ideas for Interactive Team Presentations
Creative Ideas for Interactive Team Presentations
 
zidauu _business communication.pptx /pdf
zidauu _business  communication.pptx /pdfzidauu _business  communication.pptx /pdf
zidauu _business communication.pptx /pdf
 
FEXLE- Salesforce Field Service Lightning
FEXLE- Salesforce Field Service LightningFEXLE- Salesforce Field Service Lightning
FEXLE- Salesforce Field Service Lightning
 
The Truth About Dinesh Bafna's Situation.pdf
The Truth About Dinesh Bafna's Situation.pdfThe Truth About Dinesh Bafna's Situation.pdf
The Truth About Dinesh Bafna's Situation.pdf
 
Copyright: What Creators and Users of Art Need to Know
Copyright: What Creators and Users of Art Need to KnowCopyright: What Creators and Users of Art Need to Know
Copyright: What Creators and Users of Art Need to Know
 
What is social media.pdf Social media refers to digital platforms and applica...
What is social media.pdf Social media refers to digital platforms and applica...What is social media.pdf Social media refers to digital platforms and applica...
What is social media.pdf Social media refers to digital platforms and applica...
 
A Brief Introduction About Jacob Badgett
A Brief Introduction About Jacob BadgettA Brief Introduction About Jacob Badgett
A Brief Introduction About Jacob Badgett
 
Event Report - IBM Think 2024 - It is all about AI and hybrid
Event Report - IBM Think 2024 - It is all about AI and hybridEvent Report - IBM Think 2024 - It is all about AI and hybrid
Event Report - IBM Think 2024 - It is all about AI and hybrid
 

Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf

  • 1. Biopharma PEG https://www.biochempeg.com Claudin6 (CLDN6): A Emerging Target For Solid Tumor In June 2023, BioNTech announced the first human trial data of BNT211 at the American Society of Clinical Oncology (ASCO). TORL BioTherapeutics also disclosed the first clinical data of its CLDN6 ADC drug TORL-1-23. These early clinical results provide strong support for Claudin-6 (CLDN6) as a potential target in solid tumors, especially ovarian cancers and testicular cancers. CLDN6, as a member of the Claudins family, will be a emerging target for solid tumor therapy after Claudin 18.2 (ClDN18.2). BNT211 is a combination therapy of CLDN6-targeting CAR-T and mRNA vaccine, including autologous CAR-T targeting CLDN6 and CLDN6-encoded nanoparticle mRNA vaccine CARVac. The mRNA vaccine enhances its efficacy by stimulating further expansion of CAR-T cells in vivo by expressing CLDN6 on the surface of antigen-presenting cells. Combined with the newly published study data, the researchers said that CLDN6 CAR-T infusion alone or in combination with CARVac was safe and showed efficacy in patients with CLDN6-positive cancers, and the results were superior to data from other solid tumor CAR T trials. 1. Introduction to CLDN6 The Claudins (CLDNs) protein family was first cloned and named from chicken liver by Furuse Mikio et al. in 1998, and is an important part of tight junctions (TJs). Tight junctions are mainly composed of occludin, CLDNs, and tight junction adhesion molecules. At present, 27 members of the Claudin family have been discovered, and with the deepening of research, members of the Claudins family will continue to grow, 24 of which are expressed in mammals. A large number of studies have confirmed that the Claudins family is an essential skeleton protein of TJs, mainly expressed in a tissue-specific manner in endothelial cells or epithelial cells. According to the level of sequence homology of different claudins, these members can be divided into two types, namely classic claudins and non-classical
  • 2. Biopharma PEG https://www.biochempeg.com claudins. CLDN6 belongs to the classical claudins and is homologous to CLDN1, CLDN2, CLDN3, CLDN4, CLDN5, CLDN7, CLDN8, CLDN9, CLDN10, CLDN14, CLDN15, CLDN17 and CLDN19. 2001, Turksen K. Identification of CLDN6 from differential display analysis of differentiated embryoid bodies (EBs). However, Turksen K. was not the first to isolate CLDN6. CLDN6 cDNA was first isolated from an ectoderm-specific library by Harrison S.M.'s team in 1995. Claudins members are widely distributed in different tissues and organs, and their expression has diversified characteristics. In recent years, a large number of research data have revealed that abnormal expression of Claudins is associated with a variety of tumors, and more potential targets of the Claudins family have emerged for clinical diagnosis and treatment of tumors (Figure 1). It plays a role not only in cancer, but also in other diseases. For example, aberrant expression of CLDN1 can lead to sclerosing cholangitis and ichthyosis. Increased CLDN3 is associated with decreased alveolar barrier function. In the field of cancer immunotherapy, CLDN18.2, an isomer of Claudins family member CLDN18, has become a hot target for competition by pharmaceutical companies. Now, CLDN6 is a potential target of the Claudins family, and the development of tumor-targeted drugs is also in full swing.
  • 3. Biopharma PEG https://www.biochempeg.com Figure 1 Clinical applications of claudin-targeting agents in the diagnosis, prognosis and treatment of cancer. (Source: References [1]) 2. Structure And Function of CLDN6 As one of the 27 members of the CLDN family, CLDN6 is an important molecule that makes up the tight junction between cells. The CLDN6 gene, located on chromosome 16p13.3, is composed of 220 amino acids with a molecular weight of 23kDa and contains three exons. Claudins members have similar structures. As shown in Figure 2, CLDN6 has four transmembrane domains, a short cytoplasmic N-terminal, a C-terminal cytoplasmic domain, two extracellular domains (a larger ECL1 and a smaller ECL2), and a short intracellular ring, consistent with other CLDNNS. CLDN6 has a C-terminal PDZ
  • 4. Biopharma PEG https://www.biochempeg.com binding site, which enables CLDN6 to interact with some proteins in the cell, and plays an important role in cell junctions and epithelial tissue permeability. The PDZ binding domain of ECL1 and cytoplasmic C-terminal is a typical domain of CLDN. ECL1 crosses between cells to form ion-selective pores. The position and charge of amino acids in the ECL1 region of different claudins are very different, and the difference of C-terminal sequence is another difference point that distinguishes the members of claudin. The PDZ binding sequence at the C-terminal and some potential phosphorylation sites enable claudin to directly act on its specific structural domain with ZO-1, ZO-2, ZO-3, MUPP1, etc. which contain PDZ structure in the cytoplasm, and ZO-1 and ZO-2 can directly connect with actin filament. Thus TJ protein can form a stable system with the intracellular skeleton structure. Figure 2. Structure diagram of CLDN6 (Source: References [2]) As a member of the claudin protein family, CLDN6 also has the functions of tight junction permeability regulation and barrier formation. Regarding the permeability regulation function, CLDN6 is critical for the regulation of chloride ion permeability in neonatal renal proximal tubules and the regulation of ion transport in the lymphatic sac epithelium of the inner ear. On the barrier side, CLDN6 is important for maintaining the lung epithelial barrier. In addition, CLDN6 is mainly involved in the formation of the epidermal
  • 5. Biopharma PEG https://www.biochempeg.com permeability barrier (EPB) during preterm birth. Unlike other claudin members, CLDN6 is the only CLDN with potential specificity because it activates cell adhesion signals and regulates the activity of nuclear receptors. CLDN6 is regulated by stimulation and transcription factors, DNA methylation, phosphorylation, and palmitoylation. 3. Research Projects of CLDN6 CLDN6 studies emerging immunotherapies for the treatment of cancer, including monoclonal antibodies, bispecific antibodies (BsAbs), antibody drug conjugates (ADCs) and CAR-T-cells therapy. CLDN6 is applied in monoclonal antibodies for testicular germ cell tumor, BsAbs for ovarian carcinoma, ADCs for hepatocellular carcinoma, and CAR-T-cells therapy for ovarian carcinoma. At present, there are a total of 7 clinical projects, including 1 monoclonal antibodies project, 2 bispecific antibodies projects, 2 ADC drug projects, and 2 CAR-T therapy projects. Figure 3. Clinical application of CLDN6 immunotherapy (Source: References [2])
  • 6. Biopharma PEG https://www.biochempeg.com 3.1 BNT211 & BNT142 BioNTech announced several updates to its CLDN portfolio at the 2023 ASCO Annual Meeting, including BNT211 and BNT142. Among them, the most striking is the latest research results of BNT211 for the treatment of solid tumors. BNT211 is a CLDN6-targeted CAR T cell therapy developed by BioNetech. The therapy is designed to induce robust immune responses against various CLDN6-positive solid tumors, such as ovarian, sarcoma, testicular, endometrial and gastric cancers. BNT211 is currently in a phase 1/2 trial with or without CARVac in patients with CLDN6-positive relapsed/refractory advanced solid tumors. The latest results show that in patients with CLDN6-positive relapsed/refractory advanced solid tumors, CARVac, with or without CLDN6-encoding mRNA vaccine, exhibited positive activity and manageable safety data. As of March 2023, among the 17 evaluable patients who received BNT211 with or without CARVac, the overall objective response rate (ORR) was 41%, and the disease control rate (DCR) reached 65%. One of the patients with testicular cancer who received automated BNT211 treatment achieved surgical complete response (sCR). Five additional patients achieved a partial response (PR) and three patients achieved stable disease (SD). During the automated manufacturing process, BNT211 maintained its efficacy, which supports the scale-up of the production process. BNT142 is an mRNA vaccine encoding a CD3xCLDN6 bispecific. After intravenous injection, BNT142 is directed to the liver, where the two RNAs are translated, assembled and secreted into the circulation as antibodies. Since mRNA vaccine toxicity tends to accumulate in the liver, the report of hepatotoxicity is of great significance. BNT142 is currently undergoing a Phase I dose escalation clinical trial. 3.2 TORL-1-23 TORL-1-23 is an ADC drug developed by TORL BioTherapeutics by conjugating anti-CLDN6 monoclonal antibody and tubulin inhibitor MMAE via a cleavable linker. TORL BioTherapeutics presented the first clinical data of its Claudin6 ADC drug TORL-1-23 at ASCO 2023. Phase I clinical trials have shown positive efficacy, among 25 refractory cancer patients who received an average of 5 previous treatments, 28% of patients
  • 7. Biopharma PEG https://www.biochempeg.com achieved confirmed remission. After establishing the recommended phase II dose (RP2D), TORL plans to conduct an expansion cohort study in CLDN6-positive ovarian cancer and non-small cell lung cancer (NSCLC), as well as other CLDN6-positive cancers. 3.3 DS-9606 DS-9606 is an ADC drug targeting CLDN6 developed by DaiichiSankyo. The results of preclinical research data show that the targeted Claudin6 ADC constructed on this technology platform exhibits significant anti-tumor activity. DS-9606 is currently undergoing a Phase 1 clinical study, which aims to evaluate the safety and tolerability of DS9606a in patients with advanced solid tumors. Secondary objectives of the study will evaluate the pharmacokinetic properties of DS-9606a, investigate the duration of response and progression-free survival of DS-9606a, and assess the immunogenicity of DS-9606a. 3.4 AMG 794 AMG794 is a bispecific antibody with extended half-life developed based on the bispecific T cellengager (BITE) technology platform, which can bind to human and cynomolgus monkey CLDN6 and CD3. AMG794 can reprogram T cells to kill CLDN6-expressing tumor cells and is currently enrolling patients in a Phase I clinical trial. 3.5 TJ-C64B TJ-C64B is a bispecific antibody that simultaneously targets the tumor antigen claudin6 and the T cell costimulatory molecule 4-1BB for the treatment of Claudin6-positive tumors. TJ-C64B can conditionally activate T cells by binding to CLDN6, thereby providing more precise and efficient activation of the immune system while reducing the risk of systemic toxicity. Currently, TJ-C64B is in the preclinical research stage. 4. CLDN6 In tumors And Other Diseases CLDN6 and other family proteins play an important role in the formation of tight junctions between epithelial cells and endothelial cells. The CLDN family maintains the balance of the intracellular environment through cell barriers, paracellular transport and signal transduction. Abnormal expression of family proteins such as CLDN6 can impair the
  • 8. Biopharma PEG https://www.biochempeg.com function of TJs and reduce the barrier function, leading to increased tissue permeability, and ultimately leading to the occurrence of various diseases including genetics, allergic diseases, infectious diseases of various systems, and even tumors . At present, the research on CLDN6 mainly focuses on tumors, especially ovarian cancer, testicular cancer, breast cancer, cervical cancer and endometrial cancer. 4.1 CLDN6 and tumors Tumor cells often exhibit loss of intercellular tight junctions, which may also be an important step in the development of tumor metastasis. Altered tight junction protein permeability will result in more nutrients and other factors infiltrated for tumor growth. As the main structure of tight junctions, abnormal expression of Claudins can lead to structural damage and functional impairment of epithelial cells and endothelial cells, and it is abnormally expressed in tumors of various epithelial origins. For example, the expression of Cliaudin2 in prostate cancer and breast cancer, Claudin3 in kidney cancer and bladder cancer, and Claudin4 in kidney cancer and liver cancer are down-regulated. Unlike other CLDNNS, CLDN6 is a tumor-specific protein that is present in a variety of solid tumors, including the ovaries, endometrium, lungs, stomach, and testes, but not in healthy adult tissue. Based on this, more and more studies on the role of CLDN6 in cancer have been conducted in recent years. With the continuous disclosure of research results, CLDN6 has gradually become an ideal target for tumor therapy. 4.2 CLDN6 and other diseases such as polycystic ovary syndrome Studies have confirmed that CLDN6 is highly expressed in polycystic ovary syndrome (PCOS) and Granular Cells (GC), weakening the expression of CLDN6 can inhibit the proliferation of ovarian GC in PCOS rats and induce GC apoptosis. PCOS is characterized by oligomenorrhea, hyperandrogenism, and polycystic ovarian changes, affecting 5% to 20% of women of reproductive age worldwide. In women with PCOS, GCs proliferate abnormally and are associated with overproduction of androgens in the ovaries. Another study reported that inhibiting the expression of CLDN6 can inhibit the proliferation, migration and invasion of endometriosis cells. Endometriosis is a common clinical gynecological disease, and the incidence rate is relatively high in women of childbearing age. Patients often have symptoms such as excessive menstrual flow and dysmenorrhea.
  • 9. Biopharma PEG https://www.biochempeg.com The above studies imply that CLDN6 may serve as a potential target for the treatment of PCOS or endometriosis. 5. Conclusion There are a variety of drug therapies targeting Claudin6, including monoclonal antibodies, ADCs, bispecific antibodies, and CAR-T cells. With more and more studies on the tight junction protein family, the molecular mechanism and drug research related to tumors of the CLDNs family is becoming a hot focus. Following CLDN18.2, CLDN6 is also a key member of tight junction proteins. Abnormal expression of CLDN6 plays an important role in ovarian cancer and other malignant tumors, especially gynecological tumors. At present, some positive early clinical results have been announced by ASCO in 2023, which is expected to set off a new upsurge in solid tumor research and development in the future, which deserves continuous attention. As a professional PEG supplier, Biopharma PEG supplies a variety of PEG linkers with various reactive groups in GMP or non-GMP grades to continuously assist your ADC & PROTAC research and development. References: [1] Li, Jian. "Targeting claudins in cancer: diagnosis, prognosis and therapy." American journal of cancer research 11.7 (2021): 3406. [2] Huinan Qu, Qiu Jin and Chengshi Quan“CLDN6: From Traditional Barrier Function to Emerging Roles in Cancers”Int. J. Mol. Sci. 2021, 22(24) [3] Turksen K., Troy T.C. Claudin-6: A novel tight junction molecule is developmentally regulated in mouse embryonic epithelium. Dev. Dyn. Off. Publ. Am. Assoc. Anat. 2001;222:292–300. [4]. Timothy A. Yap, et al. A phase I/II dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with prospectively confirmed claudin 6-positive solid tumors. 2023 ASCO, Abs TPS2669. [5]. Gottfried E. Konecny, et al. Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
  • 10. Biopharma PEG https://www.biochempeg.com in patients with advanced solid tumors. 2023 ASCO, Abs 3082. [6] Du H, Yang X, Fan J, et al. Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation[J]. Molecular Medicine Reports, 2021, 24(3): 1-9. [7] ASCO 2023 – Claudin 6 Makes A Splash In Ovarian Cancer, https://www.benzinga.com/general/biotech/23/06/32780740/asco-2023-claudin-6-makes- a-splash-in-ovarian-cancer [8]. John B. A. G. Haanen,et al. CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ±a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product. 2023 ASCO, Abs 2518. Related articles: [1] ADC Drugs Targeting Claudin18.2 [2] Claudin18.2 Targeted Therapies In Cancer